Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
specificStage IV includes: IVA: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two re
34
Centers
44
Active Trials
—
Cancer Funding
Top Centers for Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8(34)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | University of Illinois Cancer CenterChicago, IL High-Volume Research Center | 73.3 |
| 2 | Cancer Center at IllinoisUrbana, IL High-Volume Research Center | 71.3 |
| 3 | Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL High-Volume Research Center | 71.3 |
| 4 | Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program | 65.4 |
| 5 | Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program | 65.4 |
| 6 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 65.4 |
| 7 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 65.4 |
| 8 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 65.4 |
| 9 | Cleveland Clinic Cancer CenterCleveland, OH Active Research Program | 65.4 |
| 10 | Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program | 65.4 |
| 11 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 47.5 |
| 12 | Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, PA NCI Comprehensive Active Research Program | 47.5 |
| 13 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 47.5 |
| 14 | NCI Comprehensive Active Research Program | 47.5 |
| 15 | NCI Comprehensive Active Research Program | 47.5 |
| 16 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 47.5 |
| 17 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive Active Research Program | 47.5 |
| 18 | Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive Active Research Program | 47.5 |
| 19 | Case Comprehensive Cancer CenterCleveland, OH NCI Comprehensive Active Research Program | 47.5 |
| 20 | NCI Clinical Active Research Program | 47.5 |
| 21 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 47.5 |
| 22 | VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive Active Research Program | 47.5 |
| 23 | UMass Memorial Health Cancer CenterWorcester, MA Active Research Program | 47.5 |
| 24 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive Active Research Program | 47.5 |
| 25 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 47.5 |
| 26 | University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical Active Research Program | 47.5 |
| 27 | UAMS Winthrop P. Rockefeller Cancer InstituteLittle Rock, AR Active Research Program | 47.5 |
| 28 | Boston University Cancer CenterBoston, MA Active Research Program | 47.5 |
| 29 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive Active Research Program | 47.5 |
| 30 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 47.5 |
| 31 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive | 31.6 |
| 32 | NCI Comprehensive | 31.6 |
| 33 | 31.6 | |
| 34 | Louisiana Cancer Research CenterNew Orleans, LA | 31.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →